Quantitative Requirements of Docosahexaenoic Acid for Neural Function in Children With Phenylketonuria

NCT ID: NCT00909012

Last Updated: 2022-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 114 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-05-31
• Study Completion Date: 2013-03-31

Brief Summary

Patients with phenylketonuria (PKU) have an inborn error in the metabolism of the amino acid phenylalanine (Phe) and thus must follow a strictly controlled protein-restricted diet from early infancy. This protein-restricted diet is devoid of natural dietary sources of n-3 long chain polyunsaturated fatty acids (LC-PUFA), such as eggs, meat, milk or fish. Therefore, blood concentrations of n-3 LC-PUFA, especially of docosahexaenoic acid (DHA) are reduced in PKU children compared to healthy controls. DHA availability is considered important for optimal neurological function. Previous studies have shown that neural function of PKU children is improved by high dose supplementation of fish oil providing DHA, as shown by significant improvements of both visual evoked potential latencies and of fine motor skills and coordination, but no dose response relationship has been established so far.

This multicentric double-blind randomized trial aims at determining quantitative DHA requirements for optimal neural function in PKU children. Patients with classical PKU from several major treatment centers in Europe will be randomized to receive between 0 and 8 mg of DHA per kg body weight daily for a duration of 6 months. Biochemical (fatty acid composition of plasma phospholipids, lipoprotein metabolism and metabolic profiles), and functional testing (visual evoked potentials, fine motor skills, cognitive function and markers of immune function) will be performed at baseline and after 6 months. Intake per kg body weight will be related to outcome parameters and thus a possible dose response relationship will be defined. The results from this study are expected to contribute to the improvement of the diet of PKU patients, but they also have the potential to help defining quantitative DHA needs of healthy children.

The primary hypothesis is that supplementation with DHA improves visual function in children with PKU.

Conditions

Phenylketonuria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

1

Group Type: PLACEBO_COMPARATOR

high oleic sunflower oil

Intervention Type: DIETARY_SUPPLEMENT

placebo, which does not provide DHA

2

Group Type: EXPERIMENTAL

microalgal oil

Intervention Type: DIETARY_SUPPLEMENT

the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

3

Group Type: EXPERIMENTAL

microalgal oil

Intervention Type: DIETARY_SUPPLEMENT

the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

4

Group Type: EXPERIMENTAL

microalgal oil

Intervention Type: DIETARY_SUPPLEMENT

the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

5

Group Type: EXPERIMENTAL

microalgal oil

Intervention Type: DIETARY_SUPPLEMENT

the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

Interventions

high oleic sunflower oil

placebo, which does not provide DHA

Intervention Type: DIETARY_SUPPLEMENT

microalgal oil

the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

Intervention Type: DIETARY_SUPPLEMENT

microalgal oil

the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

Intervention Type: DIETARY_SUPPLEMENT

microalgal oil

the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

Intervention Type: DIETARY_SUPPLEMENT

microalgal oil

the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Children with classical PKU, who have been diagnosed and treated from the newborn period onwards
• Classical PKU must have been established by a baseline plasma phenylalanine (PHE) level >1200 µmol/L or detection of underlying mutations
• Children are clinically healthy besides classical PKU
• Good metabolic control (a minimum of 2 Phe-values during the last 6 months are needed with average Phe values being below 480 µmol/L in the last 6 months)
• No n-3 LC-PUFA supplementation for at least 6 months before enrolment
• Written informed consent of parents exists

Exclusion Criteria

• Severe neurological symptoms
• History of neurological disease
• Children are unable to take DHA-capsules regularly
• Acute illness, especially infections at the time of clinical examination/testing
• Children with weight/height over the 97th percentile or below the 3rd percentile
• Known hypersensitivity to fish oil products

• Minimum Eligible Age: 5 Years
• Maximum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

European Union

OTHER

Sponsor Role: collaborator

Ludwig-Maximilians - University of Munich

OTHER

Sponsor Role: lead

Responsible Party

Prof. Berthold Koletzko

Prof.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Berthold Koletzko, Prof.

Role: PRINCIPAL_INVESTIGATOR

Dr. von Hauner Children Hospital, Ludwig-Maximilians-Universitaet Muenchen

Locations

Zentrum für Kinder- und Jugendmedizin

Heidelberg, , Germany

LMU

München, , Germany

Department of Pediatrics, San Paolo Hospital Milano

Milan, , Italy

Department of Pediatrics, IFIMAV-Hospital M. Valdecill

Santander, , Spain

The Childrens Hospital Birmingham

Birmingham, , United Kingdom

Department of Pediatrics, Great Ormond Street Hospital for Sick Children

London, , United Kingdom

Countries

Germany; Italy; Spain; United Kingdom

References

Demmelmair H, MacDonald A, Kotzaeridou U, Burgard P, Gonzalez-Lamuno D, Verduci E, Ersoy M, Gokcay G, Alyanak B, Reischl E, Muller-Felber W, Faber FL, Handel U, Paci S, Koletzko B. Determinants of Plasma Docosahexaenoic Acid Levels and Their Relationship to Neurological and Cognitive Functions in PKU Patients: A Double Blind Randomized Supplementation Study. Nutrients. 2018 Dec 7;10(12):1944. doi: 10.3390/nu10121944.

Reference Type: RESULT

PMID: 30544518 (View on PubMed)

Other Identifiers

455-08

Identifier Type: -

Identifier Source: org_study_id